Herbert Irving Comprehensive Cancer Center
Investigator
Gary Schwartz, MD
Email
gks2123@cumc.columbia.edu

I am a board-certified medical oncologist and internist and chief of Columbia University Medical Center's Division of Hematology and Oncology. I am actively involved in translational and clinical research. The lab, which I direct, focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of sarcoma and melanoma. However, these agents are not disease specific and hold promise in the treatment of all solid-tumor malignancies. These laboratory studies allow for a bridge between the laboratory and the clinic, and many of these drugs that originated in the lab are now being evaluated in clinical trials. My research studies have been supported by the National Cancer Institute, the Lustgarten Foundation for Pancreatic Cancer, the Department of Defense for Breast Cancer Research, the Byrne Foundation, and the Food and Drug Administration.

I am active in a number of professional organizations, including ALLIANCE for Clinical Trials in Oncology, the American Association of Cancer Research, the American Society of Clinical Oncology, and Radiotherapy Oncology Group. For several years, I have worked closely with the National Institutes of Health and served on a number of NIH review committees. Over the course of my career, I have received many awards, including the Lustgarten Foundation for Pancreatic Research, Jeannik M. Littlefield-AACR Award in Metastatic Colon Cancer and the New York State Teaching Award in the Empire Clinical Research Investigator Program. I have also been awarded a K12 award from the NCI for the training of the next generation of physician-scientists in cancer therapy. I am involved in the teaching and mentorship of junior faculty and fellows, and I take great pride in my active participation in patient care.

I have served on the editorial boards of a number of scientific journals, and I serve as associate editor on both the Journal of Clinical Oncology and Clinical Cancer Research. I am the author of nearly 200 papers and 17 book chapters.


Clinical Studies Managed By This Investigator:
Condition Study Title
Melanoma [ CLOSED ] A study for patients with mutant melanoma using study drugs LEE011 in combination with MEK162
Solid Tumors [ CLOSED ] A study for patients with advanced malignancies (glioma, heme and cholangiocarcinoma or other solid tumors) using study drug IDH305
Solid Tumors [ CLOSED ] A study for patients with solid tumor and malignant lymphomas using study drug BAY 1143572
Cancer [ CLOSED ] A study for patients with advanced or metastatic soft tissue sarcoma using study drug Doxorubicin plus Olaratumab
Solid Tumors [ CLOSED ] A study for patients with advanced unresectable dedifferentiated liposarcoma (DDLS) using study drug Selinexor
Cancer [ CLOSED ] A study for patients with soft tissue sarcoma using study drug olaratumab
Cancer [ CLOSED ] Study safety of using glutaminase inhibitor in combination with drug (Nivolumab) in patients with renal cell carcinoma and solid tumors
Solid Tumors [ CLOSED ] Study of DS-3032b in Subjects with Advanced Solid Tumors or Lymphomas
Cancer [ CLOSED ] Study of Nivolumab in Patients with Sarcoma
Cancer [ CLOSED ] Study of Drug in Patients with Sarcoma
Cancer Study of Atezolizumab in Alveolar Soft Part Sarcoma
Cancer [ CLOSED ] Study of Drug in Patients with Epithelioid Hemangioendothelioma (EHE)
Sarcoma [ CLOSED ] Study of Drug (INCB059872) in Participants with Relapsed or Refractory Ewing Sarcoma
Cancer [ CLOSED ] Study of LY3405105 for Patients with Advanced Solid Tumors
Solid Tumors Study of ASTX295 in Patients With Solid Tumors
Cancer [ CLOSED ] Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Sarcoma [ CLOSED ] Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
Sarcoma [ CLOSED ] Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Sarcoma [ CLOSED ] Study of AMG-232 with Preoperative Radiotherapy in Subjects with Soft Tissue Sarcoma (STS)
Cancer [ CLOSED ] Study of Glutaminase Inhibitor CB-839 HCl in Subjects with Advanced Solid Tumors
Sarcoma [ CLOSED ] Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (Soft Tissue Sarcoma)
Sarcoma [ CLOSED ] ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Bone and Soft Tissue Sarcoma
Sarcoma Study of Paclitaxel With and Without Nivolumab and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma
Sarcoma Study of Envafolimab in Patients with Sarcoma or Myxofibrosarcoma
Sarcoma A Study of AL102 in Patients With Progressing Desmoid Tumors (RINGSIDE)
Sarcoma Study of Milademetan in Comparison to Trabectedin in Patients with Liposarcoma
Sarcoma Study of AGEN1181 Alone or in Combination with Balstilimab in Patients with Advanced Sarcoma
Sarcoma Study of Drug - CFT8634 in Patients with Synovial Sarcoma or SMARCB1-Null Tumors
Sarcoma Study of Drug - BI 907828 in Patients with Dedifferentiated Liposarcoma (DDLPS)